Osimertinib ( TAGRISSO)

Non-small cell lung cancer – advanced or metastatic, with EGFR mutations

Non-small cell lung cancer – adjuvant, with EGFR mutations

Non-small cell lung cancer – advanced or metastatic, with EGFR mutations

• Dose – Oral: 80 mg once daily continuously until disease progression or unacceptable toxicity

Non-small cell lung cancer – adjuvant, with EGFR mutations

• Dose – Oral: 80 mg once daily continuously up to three years

Available as 40 mg and 80 mg tablets. Tablets can be dissolved for patients unable to swallow them, please discuss with your pharmacy team. Store at room temperature.

EGFR (epidermal growth factor receptor) inhibitor

Take with or without food

If a dose is missed, patients should be instructed to take it as soon as they can if it is within 12 hours of the missed dose. If it is over 12 hours since the missed dose, patients should skip the missed dose and resume with the next scheduled dose.

Common: Diarrhea, Dry skin, Rash, Paronychia (Nail infections).

Less Common: Cardiac injury, Corneal inflammation, Visual disturbances, Fatigue, Left ventricular ejection fraction decrease, QT prolongation, Interstitial lung disease, Pneumonitis.

The adverse effects listed above are not exhaustive. Please refer to the relevant product monograph for full details.

Baseline: CBC & differential, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, calcium, potassium, magnesium, and ECG.

During treatment: alkaline phosphatase, ALT, total bilirubin, LDH, potassium, calcium and magnesium at each subsequent visit.

• May increase the risk for QT interval prolongation. Avoid concurrent therapy with drugs associated with QTc prolongation and/or Torsades de pointes, if possible. If unavoidable, monitor for QT prolongation or cardiac arrhythmias.
• This drug can impact or be impacted by metabolic enzymes for absorption and excretion. Many drugs can also affect or be affected by these enzymes, so please consult with pharmacy to assess for interactions.
• Avoid grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.
• Current drug interaction databases should be consulted for more information.

• Avoid in pregnancy and lactation.
• Ocular events have been reported. Contact lens use is a risk factor for ocular toxicity, including keratitis.
• Caution should be used when driving or operating machinery in patients who experience visual disturbances.
• Monitor for ILD (interstitial lung disease), which can be fatal.

BC Cancer. BC Cancer Drug Manual. Osimertinib. Vancouver, British Columbia: BC Cancer Agency. Available at http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Osimertinib_monograph.pdf . Updated January 1, 2020. Accessed January 22, 2024.

Lexicomp. Osimertinib Monograph. In: Lexi-Drugs. Hudson, Ohio: Lexi-Comp, Inc. Available at: https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/5928094?cesid=8vA8KFmP1G5&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dosimertinib%26t%3Dname%26acs%3Dfalse%26acq%3Dosimertinib. Updated January 24, 2024. Accessed January 29, 2024.

Cancer Care Ontario. Osimertinib Monograph. Drug Formulary. Toronto, Ontario: Cancer Care Ontario. Available at: https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44466. Updated December 2023. Accessed January 22, 2024.

AstraZeneca Canada Inc. TAGRISSO® Product Monograph. Mississauga, Ontario: AstraZeneca Canada Inc. Updated Jan 2, 2024.